조직 진단 시장 : 제품 유형, 기술, 워크플로우 단계, 용도, 최종사용자별 - 세계 시장 예측(2026-2032년)

The Tissue Diagnostics Market is projected to grow by USD 13.20 billion at a CAGR of 8.22% by 2032.

Tissue diagnostics is the clinical foundation for cancer detection, tumor classification, prognostic assessment, and therapy selection. As global cancer incidence rises, laboratories are under pressure to deliver faster, more reproducible pathology results while preserving diagnostic accuracy. The International Agency for Research on Cancer reported an estimated 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, underscoring the essential role of histopathology, immunohistochemistry, in situ hybridization, and molecular tissue testing in modern oncology care.

The tissue diagnostics landscape is being shaped by the convergence of precision medicine, companion diagnostics, laboratory automation, digital pathology, and artificial intelligence. Health systems increasingly rely on tissue-based biomarkers such as HER2, PD-L1, ER/PR, ALK, ROS1, BRAF, EGFR, and mismatch repair status to guide targeted therapy and immunotherapy decisions. This makes tissue diagnostics a strategic priority for diagnostic manufacturers, reference laboratories, hospital networks, cancer centers, and pharmaceutical partners developing biomarker-driven therapies.

Transformative Shifts in the Tissue Diagnostics Landscape

The tissue diagnostics landscape is shifting from conventional microscopy-centric workflows toward integrated, data-rich diagnostic ecosystems. Whole-slide imaging, automated staining platforms, digital pathology networks, and laboratory information system integration are improving turnaround time, traceability, and standardization across high-volume pathology operations. These shifts are especially important as pathology workforces face rising case complexity, increasing demand for subspecialty review, and broader use of tissue-based biomarker panels.

At the same time, oncology treatment pathways are becoming more biomarker dependent. Companion diagnostics and complementary diagnostics are moving tissue testing closer to therapy selection, clinical trial enrollment, and real-world evidence generation. Regulatory oversight is also evolving, including heightened scrutiny of laboratory-developed tests in the United States and stricter performance expectations under Europe's In Vitro Diagnostic Regulation, compelling organizations to prioritize analytical validity, clinical evidence, quality management, and traceable workflow documentation.

Cumulative Impact of Artificial Intelligence on Tissue Diagnostics

Artificial intelligence is becoming a practical enabler in tissue diagnostics by supporting image analysis, case prioritization, quality control, biomarker quantification, and workload optimization. AI-assisted tools can help pathologists identify regions of interest, measure staining intensity, quantify tumor-infiltrating lymphocytes, and improve consistency in tasks that are vulnerable to inter-observer variability. These capabilities are most valuable when validated on diverse datasets and embedded into regulated clinical workflows.

The cumulative impact of AI is expected to be operational as much as diagnostic. Digital pathology paired with AI can reduce manual review burden, support remote consultation, strengthen auditability, and accelerate multidisciplinary oncology decision-making. However, adoption depends on evidence-backed validation, interoperability with scanners and laboratory systems, cybersecurity controls, bias monitoring, and clear governance that keeps the pathologist central to final diagnosis.

Key Regional Insights Across the Tissue Diagnostics Landscape

North America remains a leading region for tissue diagnostics due to advanced oncology infrastructure, high adoption of companion diagnostics, strong reimbursement pathways for clinically validated tests, and a large CLIA-certified laboratory base. The United States is particularly influential because of its large cancer testing volume, established pathology networks, and ongoing FDA activity around in vitro diagnostics and laboratory-developed tests. Canada continues to advance digital pathology adoption through provincial health systems, academic hospitals, and cancer care networks.

Europe is defined by strong public health systems, academic pathology expertise, and increasing compliance requirements under the In Vitro Diagnostic Regulation. Germany, France, Italy, Spain, and the United Kingdom are investing in molecular pathology, cancer screening programs, and digital pathology modernization to improve consistency in oncology diagnostics. Asia-Pacific is a rapidly changing opportunity zone, supported by expanding cancer incidence, rising healthcare investment, and large-scale diagnostic capacity building in China, India, Japan, South Korea, Australia, and ASEAN markets.

Latin America is gaining momentum as Brazil and Mexico expand oncology access and reference laboratory capacity, although reimbursement variability, uneven access to molecular testing, and infrastructure gaps remain important constraints. The Middle East is advancing through hospital modernization, medical tourism, and national cancer control strategies, particularly in Gulf countries. Africa represents a long-term access and capacity-building opportunity, where pathology workforce shortages, specimen logistics, and affordability remain critical barriers, while international cancer initiatives and public-private partnerships are gradually improving diagnostic reach.

Key Group Insights Influencing Tissue Diagnostics Demand

The European Union is a central force in tissue diagnostics because harmonized regulatory expectations under the IVDR are reshaping clinical evidence, post-market surveillance, performance evaluation, and quality requirements for diagnostic manufacturers and laboratories. G7 markets collectively drive premium adoption of automated staining, digital pathology, AI-enabled image analysis, and companion diagnostics due to mature oncology systems, established reimbursement structures, and higher healthcare spending.

BRICS countries represent scale-driven demand, led by China and India's expanding cancer burden, Brazil's reference laboratory networks, Russia's domestic oncology needs, and South Africa's role as a regional diagnostic hub. ASEAN markets are increasingly important as Indonesia, Thailand, Vietnam, Malaysia, the Philippines, and Singapore expand hospital capacity, cancer screening programs, and access to immunohistochemistry, though adoption levels differ widely by reimbursement, workforce availability, and laboratory infrastructure.

The GCC is emerging as a high-investment setting for advanced pathology platforms, supported by healthcare diversification strategies, tertiary care expansion, and demand for localized oncology services. NATO countries overlap significantly with high-income diagnostic markets and are relevant for supply chain resilience, cybersecurity standards, and cross-border digital health collaboration, particularly as pathology data, laboratory networks, and AI systems become more connected.

Key Country Insights for Tissue Diagnostics Growth

The United States leads tissue diagnostics adoption through advanced cancer centers, high companion diagnostic utilization, broad immunohistochemistry use, and a large base of independent and hospital-based laboratories. Canada benefits from coordinated cancer care systems and provincial laboratory networks, while Mexico is expanding access through private providers, reference laboratories, and oncology service development. Brazil is Latin America's most significant tissue diagnostics hub, supported by large testing volumes and growing demand for immunohistochemistry and molecular pathology.

In Europe, the United Kingdom is accelerating digital pathology through National Health Service modernization initiatives, while Germany remains a major center for high-quality pathology infrastructure, oncology innovation, and laboratory automation. France, Italy, and Spain continue to strengthen biomarker testing access, cancer screening, and standardized pathology workflows. Russia has substantial domestic demand for oncology diagnostics, but market access, supply chain constraints, and geopolitical factors influence technology availability and procurement patterns.

China is rapidly scaling tissue diagnostics capacity as cancer care expands across public hospitals, regional medical centers, and pathology networks. India is a high-demand market driven by cancer incidence, private laboratory networks, and improving access to immunohistochemistry and molecular testing. Japan and South Korea are mature innovation markets with strong precision oncology adoption, advanced hospital systems, and established pathology expertise, while Australia combines high-quality cancer registries, accredited pathology services, and growing digital pathology implementation.

Actionable Recommendations for Tissue Diagnostics Leaders

Industry leaders should prioritize clinically validated, workflow-integrated tissue diagnostics solutions that reduce turnaround time, improve reproducibility, and support biomarker-guided oncology care. Investment should focus on automated staining, standardized pre-analytics, digital pathology interoperability, AI tools with transparent validation, and scalable data infrastructure that integrates with laboratory information systems and electronic health records.

Organizations should also strengthen regulatory readiness by aligning product development and laboratory services with FDA, CLIA, CAP, ISO, and IVDR expectations where applicable. Partnerships with cancer centers, pharmaceutical developers, and reference laboratories can accelerate companion diagnostic development and evidence generation. In emerging markets, success will depend on affordability, service support, training, reagent reliability, quality assurance, and flexible deployment models that match local pathology capacity.

Research Methodology for Tissue Diagnostics Analysis

This executive summary is built on secondary research, regulatory intelligence, and analysis of publicly available information from authoritative sources, including global cancer statistics, national health agencies, pathology professional organizations, regulatory bodies, peer-reviewed literature, and public disclosures. The research approach emphasizes verified drivers such as cancer incidence, precision medicine adoption, diagnostic workflow modernization, biomarker testing demand, and regulatory change.

Insights were synthesized by comparing regional healthcare infrastructure, reimbursement environments, technology adoption patterns, pathology workforce dynamics, and clinical demand for tissue-based biomarker testing. The methodology avoids unsupported projections and focuses on evidence-backed trends relevant to manufacturers, laboratories, healthcare providers, investors, and strategic decision-makers in the tissue diagnostics ecosystem.

Conclusion: Tissue Diagnostics in Precision Oncology

Tissue diagnostics is moving from a procedural laboratory function to a strategic pillar of precision oncology. Rising cancer incidence, expanding biomarker-driven treatment, and growing demand for faster pathology workflows are increasing the importance of reliable tissue testing across health systems. Digital pathology and AI are not replacing pathologists; they are creating tools that can improve efficiency, consistency, and access when supported by strong validation and governance.

Organizations that combine scientific credibility, regulatory discipline, interoperable technology, and regional market understanding will be best positioned to lead. The strongest opportunities will emerge where tissue diagnostics platforms connect accurate morphology, validated biomarkers, digital workflow, and actionable clinical decision support into a unified oncology diagnostics strategy.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Tissue Diagnostics Market, by Product Type

• 7.1. Instruments
  • 7.1.1. Analyzers & Scanners
  • 7.1.2. Microscopes
• 7.2. Reagents & Kits
  • 7.2.1. Enzymes & Buffers
  • 7.2.2. Staining Reagents
• 7.3. Services
  • 7.3.1. Contract Research
  • 7.3.2. Custom Assay Development

8. Tissue Diagnostics Market, by Technology

• 8.1. Flow Cytometry
  • 8.1.1. Automated Cytometers
  • 8.1.2. Benchtop Cytometers
• 8.2. Immunohistochemistry
  • 8.2.1. Chromogenic
  • 8.2.2. Fluorescent
• 8.3. In Situ Hybridization
  • 8.3.1. Cish
  • 8.3.2. Fish
• 8.4. Microarray & Sequencing
  • 8.4.1. Dna Microarray
  • 8.4.2. Next-Generation Sequencing

9. Tissue Diagnostics Market, by Workflow Stage

• 9.1. Pre-Analytical
• 9.2. Analytical
• 9.3. Post-Analytical

10. Tissue Diagnostics Market, by Application

• 10.1. Cell Imaging & Analysis
  • 10.1.1. Digital Image Analysis
  • 10.1.2. Fluorescence Microscopy
• 10.2. Companion Diagnostics
  • 10.2.1. Targeted Therapy Selection
  • 10.2.2. Treatment Efficacy Monitoring
• 10.3. Infectious Disease
  • 10.3.1. Bacterial Pathogen Detection
  • 10.3.2. Viral Pathogen Detection
• 10.4. Tumor Profiling
  • 10.4.1. Gene Expression Analysis
  • 10.4.2. Mutation Detection

11. Tissue Diagnostics Market, by End User

• 11.1. Hospitals & Diagnostic Laboratories
  • 11.1.1. Academic Hospitals
  • 11.1.2. Community Labs
• 11.2. Pharmaceutical Companies
• 11.3. Research Institutes
  • 11.3.1. Government Labs
  • 11.3.2. Private Research

12. Tissue Diagnostics Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Tissue Diagnostics Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Tissue Diagnostics Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. Abcam plc
• 16.3. Agilent Technologies, Inc.
• 16.4. Akoya Biosciences, Inc.
• 16.5. Becton, Dickinson and Company
• 16.6. Bio-Rad Laboratories, Inc.
• 16.7. BioGenex Laboratories, Inc.
• 16.8. bioMerieux SA
• 16.9. Cell Signaling Technology, Inc.
• 16.10. Charles River Laboratories International, Inc.
• 16.11. Danaher Corporation
• 16.12. F. Hoffmann-La Roche Ltd
• 16.13. GE HealthCare Technologies Inc.
• 16.14. Histoline Laboratories S.r.l.
• 16.15. Hologic, Inc.
• 16.16. Illumina, Inc.
• 16.17. Medite Medical GmbH
• 16.18. Merck KGaA
• 16.19. PerkinElmer, Inc.
• 16.20. QIAGEN N.V.
• 16.21. Quest Diagnostics Incorporated
• 16.22. Randox Laboratories Ltd
• 16.23. Sakura Finetek Japan Co., Ltd.
• 16.24. Siemens Healthineers AG
• 16.25. SLEE medical GmbH
• 16.26. Sysmex Corporation
• 16.27. Thermo Fisher Scientific Inc.